Status: current, Primitive. Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3773045010 | Vascular endothelial growth factor receptor antagonist (disposition) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
| 3773046011 | Vascular endothelial growth factor receptor antagonist | en | Synonym | Active | Case insensitive | SNOMED CT core |
| 4167521016 | VEGF antagonist | en | Synonym | Active | Case sensitive | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Vascular endothelial growth factor receptor antagonist | Is a | Receptor antagonist | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Sunitinib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Vascular endothelial growth factor receptor antagonist | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Sunitinib malate | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Bevacizumab | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Ranibizumab | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Pegaptanib sodium | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Sorafenib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Pegaptanib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Vandetanib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Axitinib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Sorafenib tosylate | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Cabozantinib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Lenvatinib mesilate | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Pazopanib hydrochloride | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Pazopanib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Lenvatinib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Ramucirumab | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Regorafenib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Aflibercept | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Brolucizumab | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Cabozantinib s-malate | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some |
Reference Sets
Qualifier value foundation reference set
Australian dialect reference set